By clicking ["Continue/Submit"], you agree that Astellas may contact you by email with information to help you connect with clinical trial sites. While we can connect you to clinical trial sites, we cannot answer questions about any investigational therapy through email. Your consent to receiving emails is not a requirement to participate in a clinical trial or study.  For more information, including how to unsubscribe at any time, see our

A study of mirabegron in young children with neurogenic detrusor overactivity

Mirabegron in Young Children Study | Astellas Clinical Trials

A study to learn how [14C]ASP0367 is processed by the body in healthy men

14C ASP0367 In Males Study | Astellas Clinical Trials

A Study of Gilteritinib (ASP2215) Combined with Chemotherapy in Children, Adolescents and Young Adults with FMS-like Tyrosine Kinase 3 (FLT3)/Internal Tandem Duplication (ITD) Positive Relapsed or Refractory Acute Myeloid Leukemia (AML)

Gilteritnib and Chemotherapy Study | Astellas Clinical Trials

A study to find the best dose of ASP5354 to show lymph nodes in people with breast cancer or melanoma during surgery

ASP5354 to Show Lymph Nodes Study | Astellas Clinical Trials

A Study of Intravesical Enfortumab Vedotin For Treatment of Patients With Non-muscle Invasive Bladder Cancer (NMIBC)

Intravesical Enfortumab Vedotin for Bladder Cancer Study | Astellas Clinical Trials

A study of the safety and tolerability of ASP7317 in adults who are losing their clear, sharp central vision due to geographic atrophy secondary to dry age-related macular degeneration

ASP7317 for Geographic Atrophy Study | Astellas Clinical Trials

A Study to Assess the Antitumor Activity, Safety, Pharmacokinetics and Biomarkers of Zolbetuximab (IMAB362) in Participants with Claudin (CLDN) 18.2 Positive, Metastatic or Advanced Unresectable Gastric and Gastroesophageal Junction (GEJ) Adenocarcinoma

Zolbetuximab Study | Astellas Clinical Trials

A Study of an Intratumoral Oncolytic Virus in Patients with Advanced Metastatic Solid Tumors

Intratumoral Oncolytic Virus Study | Astellas Clinical Trials

A Study to Assess ASP0598 Otic Solution Following Topical Application in the Ear in Subjects with Chronic Tympanic Membrane Perforation (CTMP)

ASP058 Otic Solution Study | Astellas Clinical Trials

A study to evaluate ASP0367 in participants with primary mitochondrial myopathy

ASP0367 Study for Primary Mitochondrial Myopathy | Astellas Clinical Trials

A study of ASP2138 in adults with stomach cancer or pancreatic cancer

ASP2138 Study for Stomach or Pancreatic Cancer | Astellas Clinical Trials

A study about how ASP5354 affects the body in healthy adults and in adults whose kidneys do not work well

ASP5354 for Healthy Adults and Adults with Poor Kidneys | Astellas Clinical Trials

A Study for Subjects With Prostate Cancer Who Previously Participated in an Enzalutamide Clinical Study

Prostate Cancer Study for Previous Participation in Enzalutamide  | Astellas Clinical Trials

A Study to Assess the Efficacy and Safety of IMAB362 in Combination with Nab-Paclitaxel and Gemcitabine (Nab-P + GEM) as First Line Treatment in Subjects with Claudin 18.2 (CLDN18.2) Positive, Metastatic Pancreatic Adenocarcinoma

IMAB362 with Nab P and GEM Study for Pancreatic Cancer  | Astellas Clinical Trials

A study of gilteritinib, venetoclax and azacitidine as a combined treatment for people newly diagnosed with acute myeloid leukemia

Gilteritinib Venetoclax and Azacitidine Study for Acute Myeloid Leukemia | Astellas Clinical Trials

A Study Investigating the Safety, Tolerability and Efficacy of ASP7517 in Subjects with Relapsed/Refractory Acute Myeloid Leukemia (AML) and Relapsed/Refractory Higher Risk Myelodysplastic Syndrome (MDS)

ASP7517 for Acute Myeloid Leukimia | Astellas Clinical Trials

A study to evaluate ASP0367 in participants with reduced maximum oxygen uptake due to poor systemic oxygen extraction

ASP0367 for Reduced Maxiumum Oxygen Uptake Study | Astellas Clinical Trials

A study of ASP3082 in adults with previously treated solid tumors

ASP3082 for Solid Tumors Study | Astellas Clinical Trials

A Study of ASP1570 in adults with locally advanced or metastatic solid tumors

ASP1570 for Advanced or Metastatic Tumors Study | Astellas Clinical Trials

Study of ASP7517 Alone and with Pembrolizumab in Participants with Advanced Solid Tumors Expressing WT1 Antigen

ASP7517 with Pembrolizumab Study | Astellas Clinical Trials

A Safety Surveillance Study in Subjects with Macular Degenerative Disease Treated with Human Embryonic Stem Cell-derived Retinal Pigment Epithelial Cell Therapy

Macular Degenerative Disease Study | Astellas Clinical Trials

A study to evaluate mirabegron in pediatric participants from 5 to less than 18 years of age with overactive bladder (OAB)

Mirabegron Study in Children with OAB Study | Astellas Clinical Trials

Study of ASP0739 Alone and with Pembrolizumab in Advanced Solid Tumors with NY-ESO-1 Expression Participants

ASP0739 with Pembrolizumab Study For Solid Tumors| Astellas Clinical Trials

A study of ASP0367 in people with kidneys that do not work well and in healthy people

ASP0367 Study for Adults with Poor Kidneys | Astellas Clinical Trials

Enfortumab vedotin and pembrolizumab vs. chemotherapy alone in untreated locally advanced or metastatic urothelial cancer

Enfortumab Vedotin and Pembrolizumab vs Chemotherapy Study | Astellas Clinical Trials

ABOUT CLINICAL TRIALS

FAQS

Have questions about or want more information about A Study of LY3471851 in Participants With Gastric Cancer? Contact us by filling out your information below and we’ll respond to you.

Purpose [I would like…]

Requestor Information [I am…]

Access to anonymized individual participant level data will not be provided for this trial as it meets one or more of the exceptions described on www.clinicalstudydatarequest.com under "Sponsor Specific Details for Astellas."

OAB patients whose physician has made the decision to prescribe Betmiga® as part of routine clinical practice and who are about to start treatment

178-ma-1002-clrr-03-disc02-en-final-02.pdf

A study to understand the impact of Betmiga® on patients quality of life,  satisfaction with treatment, how long patients remain on treatment, patterns of healthcare resource utilisation, and safety as prescribed by the physicians in routine clinical practice.

A prospective non-interventional study in overactive bladder (OAB) patients prescribed Betmiga® as part of routine clinical practice

Single arm, hybrid model study, observing patients on Betmiga under conditions of routine clinical practice, with some element of retrospective data collection 2 years prior to enrolment of the study

CN CDE Number

EudraCT Number

jRCT Number

NCT ID

Patient Level Data

Product ST Name

Therapeutic Area

Link to results on the Astellas Clinical Study Results website.

Site ES34010 Policlínico de Vigo, S.A.-POVISA

Site GB44005 Bradford Royal Infirmary

Site GR30003 University Hospital of Patras

Site GB44003 Derriford Hospital

Site ES34009 Hospital Comarcal Santiago Apostol

Site DK45004 Regionshospitalet Herning

Site GB44017 Sunderland Royal University Hospital

Site IE35303 Kerry General Hospital

Site CZ42006 Hospital Kyjov

Site SE46002 Urologkliniken Carlanderska

Site GB44016 Addenbrookes Hospital

Site GR30008 University Hospital of Ioannina

Site SK42106 UROCENTRUM LEVICE, s.r.o.

Site ES34012 H. de Mendaro

Site GB44013 Hinchingbrooke Hospital

Site GB44008 Croydon University Hospital

Site IE35302 Coombe Hospital

Site SK42102 UROAMB, s.r.o.

Site GR30001 General Hospital of Athens "Alexandra"

Site CZ42004 Krajská nemocnice Tomáše Bati

Site ES34019 Hospital Universitario Lucus Augusti

Site CZ42002 Fakultni nemocnice Kralovske Vinohrady

Site ES34021 H. de Donostia

Site CZ42008 Oblastni nemocnice Pribram

Site ES34017 Hospital de Mollet

Site GB44018 Salisbury District Hospital

Site GR30002 University Hospital of Crete

Site GR30005 University Hospital of Larissa

Site SK42104 Urologicka ambulancia, Miramed, sro

Site GB44015 University Hospital Coventry

Site CZ42007 MEDICON a.s.

Site GR30011 General Hospital of Heraklion 'Venizelio-Pananio'

Site ES34011 Hospital del Rio Hortega

Site DK45003 Sygehus Vendsyssel, Frederikshavn

Site SK42101 Univerzitná nemocnica Bratislava - Kramáre

Site CZ42003 Fakultni nemocnice Brno-Bohunice

Site GB44004 Southern General Hospital

Site GB44010 The Freeman Hospital

Site SK42105 ProCare Ziar nad Hronom

Site GB44001 Medway Hospital

Site GB44009 St. Richards Hospital

Site ES34007 Hospital Universitario Vall D'Hebron

Site GR30009 PGH Laiko

Site GB44011 Royal Blackburn Hospital

Site GB44019 Northern Devon Healthcare

Site GR30006 Papageorgiou General Hospital

Site GB44014 The Queen Elizabeth Hospital King's Lynn NHS Trust

Site GB44006 New Cross Hospital

Site SK42103 CMFF, sro

Site GB44007 Northampton General Hospital

Site GR30012 Papageorgiou General Hospital of Thessaloniki

Site ES34015 Centro Médico Teknon

Site IE35304 Midland Regional Hospital

Site ES34005 Corporació Sanitaria Parc Taulí

Site ES34020 Hospital Universitario Basurto

Site CZ42009 UROMEDA s. r. o.

Site GR30013 University Hospital of Ioannina

Site SK42107 Private Urological Care Center

Site GR30007 Sismanoglio General Hospital

Site GB44002 The Royal Berkshire Hospital

Non-Interventional Study Assessing Quality of Life, Treatment Satisfaction, Resource Utilisation, and Persistence with Treatment in Overactive Bladder (OAB) Patients Prescribed Betmiga® - A Multicenter Non-interventional Post Authorisation Study (PAS)

Quality of life (QoL) based on the Overactive bladder questionnaire (OAB-q) subscales

Based on Treatment Satisfaction Visual Analogue Scale (TS-VAS)

QoL based on Work Productivity Activity Index:Specific Health Problem (WPAI:SHP) and EUROQOL 5-DIMENSIONS (EQ5D)

Overactive bladder (OAB) healthcare resources are captured by the investigator and include: healthcare visits, medical interventions, number of incontinence pads used in last 7 days, invasive/surgical treatments of OAB symptoms and any other investigations of OAB (including clinical interpretation if available)

Disease progression is defined by occurrence of invasive/surgical treatment of OAB symptoms during the study. Overactive Bladder (OAB) treatments include e.g. Botulinum toxin type A, Sacral Neural Stimulation (SNS), Percutaneous tibial nerve stimulation (PTNS)

Adverse Events (AEs), Adverse Drug Reaction (ADR)

This composite summary includes the following items:
  - Number and percentage of patients who switched treatment, and to what treatment they were switched.
  - Number and percentage of patients who stopped treatment and reasons associated with discontinuation.
  - Number of treatment days on current treatment.
  - Time from treatment initiation to discontinuation or switching to another treatment.
  - Time from treatment initiation to prescription of additional oral OAB treatment and reasons for combination treatment.